Osteoarthritis Management: From Conservative Care to Surgery

Abstract

Osteoarthritis (OA) is the most prevalent form of arthritis, representing a significant global health burden, particularly among aging populations. This review synthesizes current evidence spanning epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic strategies, and the spectrum of management approaches, from non-pharmacological and pharmacological interventions to surgical options. Emphasis is placed on mechanism-based therapies, recent advances, and guideline-driven recommendations, providing healthcare professionals with practical, evidence-based insights for optimizing patient outcomes. Reference placeholders are included for key studies and guidelines.

Introduction

Osteoarthritis (OA) is a chronic, progressive joint disorder characterized by degeneration of articular cartilage, subchondral bone remodeling, osteophyte formation, and varying degrees of synovial inflammation. It is the most common form of arthritis worldwide and a leading cause of pain, disability, and reduced quality of life, particularly among older adults. Once considered a simple “wear-and-tear” condition, OA is now recognized as a complex disease influenced by mechanical, inflammatory, metabolic, genetic, and environmental factors.

The condition commonly affects the knees, hips, hands, and spine, leading to chronic pain, stiffness, reduced mobility, and functional limitations. Rising life expectancy, increasing obesity rates, and sedentary lifestyles have contributed to the growing global burden of OA. Given its multifactorial etiology and diverse clinical presentation, OA management requires an individualized, patient-centered approach that combines non-pharmacological interventions, pharmacological therapies, and, when necessary, surgical treatment. This review provides an up-to-date overview of OA management strategies based on current evidence and recommendations from major international guidelines, including ACR, EULAR, and OARSI.

Epidemiology / Disease Burden

OA affects over 300 million people globally, with prevalence rising in tandem with aging demographics and obesity rates [4]. In the United States, radiographic knee OA is found in approximately 37% of individuals over 60 years, while symptomatic OA affects 10-15% of adults over 60 worldwide. OA is a leading cause of disability and reduced mobility, with significant socioeconomic impact, accounting for substantial healthcare expenditures and work absenteeism. The disease burden is anticipated to rise with increasing life expectancy and the global obesity epidemic.

Pathophysiology

OA is fundamentally a disease of the whole joint, involving cartilage degradation, subchondral bone remodeling, osteophyte formation, and synovial inflammation. Mechanical stress, biochemical factors, and genetic predisposition interact to initiate and perpetuate cartilage matrix breakdown via upregulation of catabolic enzymes like matrix metalloproteinases (MMPs) and aggrecanases. Pro-inflammatory cytokines, notably IL-1β and TNF-α, further drive synovitis and pain. Recent evidence implicates subchondral bone changes and altered chondrocyte metabolism as crucial contributors to disease progression.

Risk Factors

Major risk factors include age, female sex (particularly post-menopausal), obesity, prior joint injury, repetitive mechanical stress, and genetic susceptibility. Obesity exerts both biomechanical and metabolic pro-inflammatory effects, making weight management a cornerstone intervention. Additional risk factors comprise joint malalignment, muscle weakness, and certain metabolic disorders (e.g., diabetes, hemochromatosis).

Clinical Features

OA typically presents with joint pain exacerbated by activity and relieved by rest, morning stiffness lasting less than 30 minutes, crepitus, decreased range of motion, and sometimes joint swelling. The knees, hips, hands, and spine are most commonly affected. Advanced disease may manifest with joint instability, deformity, and significant functional impairment. Clinical examination and patient-reported outcomes are essential for assessing disease impact and guiding management.

Diagnosis

The diagnosis of OA is primarily clinical, supported by characteristic symptoms and physical findings. Radiographic imaging (X-rays) reveals joint space narrowing, osteophyte formation, subchondral sclerosis, and cysts but often correlates poorly with symptom severity. MRI may be useful in selected cases to assess soft tissue and early cartilage changes, especially in atypical presentations. Laboratory tests are generally non-specific and used to exclude other causes of arthritis. Contemporary guidelines recommend a clinical diagnosis in typical cases and imaging for confirmation or exclusion of alternative diagnoses.

Treatment & Management

Management of OA is multimodal and individualized, focusing on pain control, functional improvement, and disease progression mitigation.Non-pharmacological interventions are foundational, including patient education, weight loss, structured exercise programs (aerobic and strengthening), and physical therapy. Assistive devices and occupational therapy may benefit functionally limited patients.Pharmacological options comprise topical NSAIDs (first-line for knee/hand OA per ACR/EULAR), oral NSAIDs (lowest effective dose due to GI/CV risk), and intra-articular corticosteroids for acute flares. Paracetamol has limited efficacy and is no longer widely recommended as monotherapy. Symptomatic slow-acting drugs for OA (SYSADOAs), such as glucosamine and chondroitin, remain controversial due to mixed evidence. Opioids, duloxetine, and intra-articular hyaluronic acid are reserved for selected refractory cases.Surgical intervention, notably total joint arthroplasty, is indicated for advanced OA with persistent pain and functional decline unresponsive to conservative care. Arthroscopic procedures are generally discouraged except for mechanical symptoms (e.g., locking). Perioperative optimization and rehabilitation are critical for outcome maximization.

Recent Advances / Emerging Therapies

Recent research has focused on disease-modifying OA drugs (DMOADs), regenerative therapies, and biologics. Intra-articular platelet-rich plasma (PRP) and stem cell therapies show promise in early trials but require further validation. Monoclonal antibodies targeting nerve growth factor (e.g., tanezumab) have demonstrated analgesic efficacy but raise concerns about rapidly progressive OA and safety. Advances in imaging, biomarkers, and personalized medicine may facilitate earlier diagnosis and tailored interventions in the future.

Guideline Recommendations

Major international guidelines (ACR 2019, EULAR 2019, OARSI 2019) uniformly emphasize non-pharmacological interventions as first-line therapy, with pharmacological options layered according to symptoms and comorbidity profiles. Weight loss, exercise, and education are universally endorsed. Topical NSAIDs are favored for localized OA, while oral NSAIDs are used cautiously. Routine use of opioids and arthroscopy is discouraged. Indications for surgery are reserved for refractory, severe cases. Guideline recommendations are evolving as newer therapies undergo robust evaluation.

Conclusion

OA management is rapidly evolving, with growing emphasis on mechanism-based, personalized, and patient-centered care. Advances in the understanding of osteoarthritis pathophysiology have highlighted the importance of tailoring treatment strategies according to individual patient characteristics, disease severity, comorbidities, and functional goals. Optimal outcomes are best achieved through integrated, multidisciplinary approaches that combine lifestyle modification, exercise therapy, pharmacological interventions, rehabilitation, and surgical options when appropriate. Adherence to evidence-based guideline recommendations remains essential for ensuring consistent and effective care across diverse patient populations.

While current therapeutic strategies primarily focus on symptom relief, pain reduction, maintenance of joint function, and improvement in quality of life, ongoing research is expanding the horizons of OA treatment. Novel therapies targeting inflammatory pathways, cartilage regeneration, subchondral bone remodeling, and disease progression are being actively investigated. These emerging disease-modifying osteoarthritis drugs (DMOADs) and regenerative medicine approaches hold significant promise for altering the natural course of the disease rather than simply managing its symptoms. As research continues to advance, the future of OA management is expected to move beyond symptomatic treatment toward interventions capable of preserving joint health, slowing structural deterioration, and improving long-term patient outcomes.